UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): September 9, 2015


 

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

 


 

Florida 001-33357 65-0643773

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

(IRS Employer

Identification No.)

 

 

2 Snunit Street 20100
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code +972-4-988-9488

 

(Former name or former address, if changed since last report.)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

 

 

Item 8.01.Other Events

 

On September 9, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing positive interim data from the Company’s phase I/II clinical trial of 1mg/kg of PRX-102 for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01.Financial Statements and Exhibits

 

(d)Exhibits

 

99.1Press release dated September 9, 2015

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTALIX BIOTHERAPEUTICS, INC.
     
Date: September 9, 2015 By: /s/ Moshe Manor
    Name: Moshe Manor
    Title: President and
    Chief Executive Officer

  

 3